Abstract
Evidence from psychopharmacological functional neuroimaging begins to elucidate the neurochemical mechanisms of cognitive control. Here the role of dopamine in two subcomponent processes of cognitive control is discussed: the active maintenance and the flexible updating of goal-relevant representations. A range of studies have highlighted a role for the prefrontal cortex (pFC) and its modulation by dopamine in the active maintenance of distractor-resistant goal-relevant representations. This work suggests that dopamine might modulate top-down signals from the pFC, thereby increasing the activity of posterior cortical regions that process goalrelevant representations and rendering them distractor-resistant. Conversely, other studies highlight a role for dopamine in the basal ganglia in cognitive switching, which might reflect a modulation of the selective gating of cortical cognitive and motor programs. We present a working hypothesis that integrates these two disparate literatures and states that the flexible adaptation of current goal-relevant representations is mediated by modulatory influences of activity in the dopamine-sensitive basal ganglia on connectivity between the prefrontal cortex and posterior cortex.
Current Pharmaceutical Design
Title: Dopaminergic Modulation of Cognitive Control: Distinct Roles for the Prefrontal Cortex and the Basal Ganglia
Volume: 16 Issue: 18
Author(s): Martine van Schouwenburg, Esther Aarts and Roshan Cools
Affiliation:
Abstract: Evidence from psychopharmacological functional neuroimaging begins to elucidate the neurochemical mechanisms of cognitive control. Here the role of dopamine in two subcomponent processes of cognitive control is discussed: the active maintenance and the flexible updating of goal-relevant representations. A range of studies have highlighted a role for the prefrontal cortex (pFC) and its modulation by dopamine in the active maintenance of distractor-resistant goal-relevant representations. This work suggests that dopamine might modulate top-down signals from the pFC, thereby increasing the activity of posterior cortical regions that process goalrelevant representations and rendering them distractor-resistant. Conversely, other studies highlight a role for dopamine in the basal ganglia in cognitive switching, which might reflect a modulation of the selective gating of cortical cognitive and motor programs. We present a working hypothesis that integrates these two disparate literatures and states that the flexible adaptation of current goal-relevant representations is mediated by modulatory influences of activity in the dopamine-sensitive basal ganglia on connectivity between the prefrontal cortex and posterior cortex.
Export Options
About this article
Cite this article as:
van Schouwenburg Martine, Aarts Esther and Cools Roshan, Dopaminergic Modulation of Cognitive Control: Distinct Roles for the Prefrontal Cortex and the Basal Ganglia, Current Pharmaceutical Design 2010; 16 (18) . https://dx.doi.org/10.2174/138161210791293097
DOI https://dx.doi.org/10.2174/138161210791293097 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Xiaoyao Pill Improves the Affective Dysregulation of Sleep-deprived Female Mice by Inhibiting Brain Injury and Regulating the Content of Monoamine Neurotransmitter
Current Pharmaceutical Biotechnology Pathological Gambling: Neuropsychopharmacology and Treatment
Current Psychopharmacology Editorial [Hot Topic: Nitric Oxide: Implications for the Etiology & Treatment of Central Nervous System Disorders (Guest Editor: Giuseppe Di Giovanni)]
CNS & Neurological Disorders - Drug Targets Mean Diffusivity in the Dopaminergic System and Neural Differences Related to Dopaminergic System
Current Neuropharmacology Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Clozapine and Olanzapine but not Risperidone Impair the Pre-Frontal Striatal System in relation to Egocentric Spatial Orientation in a Y-Maze
Current Neurovascular Research Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science A New Interpretative Paradigm for Conformational Protein Diseases
Current Protein & Peptide Science Myelination in Bipolar Patients and the Effects of Mood Stabilizers on Brain Anatomy
Current Pharmaceutical Design Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Novel Medication Targets for the Treatment of Alcoholism: Preclinical Studies
Recent Patents on CNS Drug Discovery (Discontinued)